|
|
|
|
LEADER |
04572nam a2200985Ia 4500 |
001 |
10.1002-jcla.23713 |
008 |
220427s2021 CNT 000 0 und d |
020 |
|
|
|a 08878013 (ISSN)
|
245 |
1 |
0 |
|a Associations of PER3 polymorphisms with clopidogrel resistance among Chinese Han people treated with clopidogrel
|
260 |
|
0 |
|b John Wiley and Sons Inc
|c 2021
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1002/jcla.23713
|
520 |
3 |
|
|a Background: Changes in circadian rhythm are related to various diseases, such as immune system diseases and cardiovascular diseases. The PERIOD3 (PER3) clock gene is one of the most important genes in the rhythm regulation system. Our goal was to evaluate the possible association between the PER3 rs228729 (T/C) polymorphism or PER3 rs2797685(T/C) polymorphism and clopidogrel resistance (CR) and to study the impact of clinical baseline data on clopidogrel resistance. Methods: PER3 polymorphisms rs2797685 (T/C) and rs228729 (T/C) were assessed in 156 patients with (72) and without (84) CR. Blood samples were collected and analyzed after the application of clopidogrel for interventional therapy. Results: Age, albumin, PLT, and PCT levels influenced the risk of CR (p < 0.05). For rs2797685, when the PCT value was greater than 0.19, patients with the TT + TC genotype had an increased risk of clopidogrel resistance compared with those with the CC genotype (PCT ≥ 0.19, p = 0.014; PCT p = 0.004). In patients with albumin values greater than 40 or PCT greater than 0.19, those with the rs228729 TT + TC genotype had an increased risk of clopidogrel resistance compared with those with the CC genotype (albumin≥40, TT+TC:CC, p = 0.01, albumin p = 0.005; PCT ≥ 0.19, TT+TC:CC, p < 0.001, PCT p = 0.004). Logistic regression analysis of clinical baseline data and genotype showed that high albumin is a protective factor against clopidogrel resistance. The PER3 gene polymorphism has no clear correlation with clopidogrel resistance. Conclusion: In summary, our research shows that PER3 SNPs may be helpful to assess the pathogenesis of CR. © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC
|
650 |
0 |
4 |
|a acetylsalicylic acid
|
650 |
0 |
4 |
|a acute coronary syndrome
|
650 |
0 |
4 |
|a adult
|
650 |
0 |
4 |
|a aged
|
650 |
0 |
4 |
|a Aged
|
650 |
0 |
4 |
|a albumin
|
650 |
0 |
4 |
|a albumin blood level
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a Asian continental ancestry group
|
650 |
0 |
4 |
|a Asian Continental Ancestry Group
|
650 |
0 |
4 |
|a Blood Platelets
|
650 |
0 |
4 |
|a case control study
|
650 |
0 |
4 |
|a Case-Control Studies
|
650 |
0 |
4 |
|a circadian rhythm signaling protein
|
650 |
0 |
4 |
|a clopidogrel
|
650 |
0 |
4 |
|a clopidogrel
|
650 |
0 |
4 |
|a Clopidogrel
|
650 |
0 |
4 |
|a clopidogrel resistance
|
650 |
0 |
4 |
|a controlled study
|
650 |
0 |
4 |
|a drug effect
|
650 |
0 |
4 |
|a drug resistance
|
650 |
0 |
4 |
|a Drug Resistance
|
650 |
0 |
4 |
|a ethnic group
|
650 |
0 |
4 |
|a Ethnic Groups
|
650 |
0 |
4 |
|a female
|
650 |
0 |
4 |
|a Female
|
650 |
0 |
4 |
|a gene
|
650 |
0 |
4 |
|a gene frequency
|
650 |
0 |
4 |
|a genetic association
|
650 |
0 |
4 |
|a Genetic Association Studies
|
650 |
0 |
4 |
|a genetic association study
|
650 |
0 |
4 |
|a genetic risk
|
650 |
0 |
4 |
|a genetics
|
650 |
0 |
4 |
|a genotype
|
650 |
0 |
4 |
|a groups by age
|
650 |
0 |
4 |
|a Han Chinese
|
650 |
0 |
4 |
|a high risk patient
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a human cell
|
650 |
0 |
4 |
|a Humans
|
650 |
0 |
4 |
|a loading drug dose
|
650 |
0 |
4 |
|a Logistic Models
|
650 |
0 |
4 |
|a major clinical study
|
650 |
0 |
4 |
|a male
|
650 |
0 |
4 |
|a Male
|
650 |
0 |
4 |
|a metabolism
|
650 |
0 |
4 |
|a middle aged
|
650 |
0 |
4 |
|a Middle Aged
|
650 |
0 |
4 |
|a multivariate analysis
|
650 |
0 |
4 |
|a Multivariate Analysis
|
650 |
0 |
4 |
|a PER3 gene
|
650 |
0 |
4 |
|a PER3 protein, human
|
650 |
0 |
4 |
|a percutaneous coronary interventions
|
650 |
0 |
4 |
|a Period Circadian Proteins
|
650 |
0 |
4 |
|a PERIOD3
|
650 |
0 |
4 |
|a platelet count
|
650 |
0 |
4 |
|a plateletcrit
|
650 |
0 |
4 |
|a Polymorphism, Single Nucleotide
|
650 |
0 |
4 |
|a single nucleotide polymorphism
|
650 |
0 |
4 |
|a single nucleotide polymorphism
|
650 |
0 |
4 |
|a single-nucleotide polymorphisms
|
650 |
0 |
4 |
|a statistical model
|
650 |
0 |
4 |
|a therapy resistance
|
650 |
0 |
4 |
|a thrombocyte
|
700 |
1 |
|
|a Chen, X.
|e author
|
700 |
1 |
|
|a Su, J.
|e author
|
700 |
1 |
|
|a Xu, Z.
|e author
|
700 |
1 |
|
|a Yang, J.
|e author
|
700 |
1 |
|
|a Yin, F.
|e author
|
700 |
1 |
|
|a Yu, Q.
|e author
|
700 |
1 |
|
|a Zheng, N.
|e author
|
700 |
1 |
|
|a Zhong, J.
|e author
|
773 |
|
|
|t Journal of Clinical Laboratory Analysis
|